Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1222 (LINC01222) is a human long intergenic non-coding RNA (lincRNA), which means it is an RNA transcript longer than 200 nucleotides that does not overlap any protein-coding gene and lacks protein-coding potential[3][5]. It is encoded in the human genome as gene 102800316 (NCBI Gene) and is also referenced by the alias TCONS_00000112[3]. LINC01222 belongs to a large class of lincRNAs known to regulate gene expression at various levels, including chromatin modification, RNA stability, and transcription, through a range of mechanisms[5]. There are no specific reports directly linking LINC01222 to particular biological pathways, disease roles, or therapeutically actionable functions at this time, and it is not considered a therapeutic target[1][3][5]. Other lincRNAs are established as regulators of cell fate and disease progression, but the unique contributions of LINC01222 remain to be elucidated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1222 (LINC01222).